Immuneering Corporation (NASDAQ:IMRX) Director Thomas J. Schall Purchases 9,500 Shares

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Thomas J. Schall bought 9,500 shares of the company's stock in a transaction dated Friday, June 27th. The stock was purchased at an average price of $3.66 per share, with a total value of $34,770.00. Following the completion of the transaction, the director directly owned 52,885 shares in the company, valued at approximately $193,559.10. This represents a 21.90% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immuneering Stock Performance

Shares of IMRX stock traded up $0.15 on Wednesday, hitting $3.59. The company had a trading volume of 705,321 shares, compared to its average volume of 2,537,317. Immuneering Corporation has a twelve month low of $1.00 and a twelve month high of $3.87. The firm has a market cap of $129.20 million, a P/E ratio of -1.83 and a beta of 0.37. The stock's 50-day moving average is $1.87 and its two-hundred day moving average is $1.80.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). Equities research analysts predict that Immuneering Corporation will post -1.86 EPS for the current year.

Hedge Funds Weigh In On Immuneering

Hedge funds have recently bought and sold shares of the company. HighTower Advisors LLC boosted its position in shares of Immuneering by 33.7% during the 4th quarter. HighTower Advisors LLC now owns 71,360 shares of the company's stock valued at $157,000 after purchasing an additional 18,000 shares in the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Immuneering during the 4th quarter worth approximately $390,000. XTX Topco Ltd boosted its holdings in shares of Immuneering by 177.2% during the 4th quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock worth $72,000 after buying an additional 20,871 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Immuneering during the 4th quarter worth approximately $47,000. Finally, Bridgeway Capital Management LLC increased its stake in shares of Immuneering by 77.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after acquiring an additional 22,400 shares in the last quarter. Institutional investors own 67.65% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on IMRX. Needham & Company LLC reiterated a "buy" rating and set a $9.00 price objective on shares of Immuneering in a research report on Wednesday, June 18th. Oppenheimer reduced their price target on Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Chardan Capital reiterated a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Finally, Mizuho boosted their target price on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, Immuneering currently has an average rating of "Moderate Buy" and an average price target of $13.25.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.